{"title":"edoxaban的临床发展。第二阶段研究","authors":"Manuel Almendro-Delia, Rafael Hidalgo-Urbano","doi":"10.1016/S1131-3587(16)30018-8","DOIUrl":null,"url":null,"abstract":"<div><p>Edoxaban is a direct inhibitor of factor Xa that has been evaluated for the prevention of cerebral and systemic thromboembolic events in patients with nonvalvular atrial fibrillation. A comprehensive program of phase-II studies has demonstrated that administration of a dose of 30 or 60 mg once a day rather than twice daily is associated with fewer hemorrhagic events than warfarin. The dose should be lower in certain conditions (e.g. patients with moderate renal impairment or a body weight ≤60 kg and those taking P-glycoprotein inhibitors) in order to reduce the risk of hemorrhagic complications.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30018-8","citationCount":"0","resultStr":"{\"title\":\"Desarrollo clínico del edoxabán. Estudios en fase II\",\"authors\":\"Manuel Almendro-Delia, Rafael Hidalgo-Urbano\",\"doi\":\"10.1016/S1131-3587(16)30018-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Edoxaban is a direct inhibitor of factor Xa that has been evaluated for the prevention of cerebral and systemic thromboembolic events in patients with nonvalvular atrial fibrillation. A comprehensive program of phase-II studies has demonstrated that administration of a dose of 30 or 60 mg once a day rather than twice daily is associated with fewer hemorrhagic events than warfarin. The dose should be lower in certain conditions (e.g. patients with moderate renal impairment or a body weight ≤60 kg and those taking P-glycoprotein inhibitors) in order to reduce the risk of hemorrhagic complications.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1131-3587(16)30018-8\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358716300188\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358716300188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Desarrollo clínico del edoxabán. Estudios en fase II
Edoxaban is a direct inhibitor of factor Xa that has been evaluated for the prevention of cerebral and systemic thromboembolic events in patients with nonvalvular atrial fibrillation. A comprehensive program of phase-II studies has demonstrated that administration of a dose of 30 or 60 mg once a day rather than twice daily is associated with fewer hemorrhagic events than warfarin. The dose should be lower in certain conditions (e.g. patients with moderate renal impairment or a body weight ≤60 kg and those taking P-glycoprotein inhibitors) in order to reduce the risk of hemorrhagic complications.
期刊介绍：
Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
